A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

NCT05950165 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: CHO-H01
DRUG: CHO-H01 at RP2D
DRUG: Lenalidomide

Sponsor

Cho Pharma Inc.